TRAIL-induced apoptosis of ovarian cancer cell lines with selective drug resistance;Untersuchungen zur TRAIL-induzierten apoptose von ovarialkarzinomzelllinien mit selektiver zytostatikaresistenz

Geburtshilfe und Frauenheilkunde

Volumn 65, Issue 11, 2005, Pages 1064-1073

  Meinhold Heerlein, Ivo ^a   Borges Engeby, K ^b   Grunn U ^b   Bauerschlag, D ^a   Maass, N ^a   Mundhenke, C ^a   Jonat, Walter ^a   Bauknecht, T ^b,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Apoptosis; Chemotherapy resistance; Ovarian cancer cell lines; TRAIL

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; ETOPOSIDE; FORMAZAN; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER;

EID: 29244476528     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872998     Document Type: Article

References (30)

1. Reles A, Utz I, Lichtenegger W. Das p53-Tumorsuppressorgen - prädiktiver Faktor bei Chemotherapie mit Taxanen? Geburtsh Frauenheilk 2003; 63. DOI: 10.1055/s-2003-815161
2. Grab D, Flock F, Stöhr I, Rieber A, Nüssle S, Brambs HJ, Fenchel S, Reske SN, Kreienberg R. Diagnostische Wertigkeit von Sonographie, Kernspintomographie und Positronenemissionstomographie zur Beurteilung der Dignität von Adnextumoren bei prämenopausalen Patientinnen. Geburtsh Frauenheilk 2000; 60: 544-552
3. Wagner U, Pfisterer J, Jackisch C, Meier W, du Bois A. Neue Hoffnungsträger in der Therapie des Ovarialkarzinoms: Aktuelle Studien zu neuen Therapieansätzen der Studiengruppe Ovarialkarzinom der AGO. Geburtsh Frauenheilk 2004; 64: 777
4. Du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. J Natl Cancer Inst 2003; 95: 1320-1329
5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3183-3185
6. Huober J. Kongressbericht. 3. Tübinger Airport Meeting - Therapie der Mamma- und Ovarialkarzinoms. Geburtsh Frauenheilk 2004; 64: 212-213
7. Du Bois A, Lück HJ, Bauknecht T. 2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geburtsh Frauenheilk 2000; 60: 41-58
8. Meinhold-Heerlein I, Maass N, Jonat W. Apoptose und Anti-Angiogenese als therapeutische Prinzipien in der gynäkologischen Onkologie. Der Gynäkologe 2004; 37: 222-229
9. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776
10. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes & Development 1999; 13: 239-252
11. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2 L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 6. Immunity 2000; 12: 611-620
12. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem; 277: 22320-22329
13. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 14: 155-162
14. Keane MM, Ettenberg SA, Nau MM, Russell EK, Liplowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741
15. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Balla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61: 759-763
16. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001; 31: 380-390
17. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-346
18. www.gene.com/gene/pipeline/status/oncology/apo21
19. www.hgsi.com
20. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668-3676
21. Almasan A, Ashkenazi A. Apo2 L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003; 14: 337-348
22. Tomek S, Horak P, Pribill I, Haller G, Rossler M, Zielinski CC, Pils D, Krainer M. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 2004; 94: 107-114
23. Vignati S, Codegoni A, Polato F, Broggini M. TRAIL activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002; 38: 177-183
24. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000; 256: 42-49
25. Lancaster JM, Sayer R, Blachette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. High expression of tumor necrosis factor-related apotosis-inducing ligand is associated with favourable ovarian cancer survival. Clin Cancer Res 2003; 9: 762-766
26. Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG, de Vries EG. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gyncol Oncol 2004; 92: 794-800
27. Lane D, Cartier A, L'Esperance S, Cote M, Rancourt C, Piche A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol 2004;93:594-604
28. Frankfurt OS, Krishan A. Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism. Chem Biol Interact 2003; 145: 89-99
29. Ozoren N, Fisher MJ, Kim K, Liu CX, Genin A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA, El-Deiry WS. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000; 16: 917-925
30. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 2003; 63: 4521-4526